- Published on
Emergency and Acute Medicine – Trigeminal Neuralgia
Trigeminal neuralgia is a distinct facial pain syndrome involving the trigeminal nerve, which provides sensory innervation to the face, oral cavity, nasal mucosa, and cornea. Also known as tic douloureux, the condition is characterized by brief, recurrent episodes of severe facial pain. It most commonly affects individuals over 50 years of age and occurs more frequently in women.
The disorder is divided into two forms. Classical trigeminal neuralgia occurs without an identifiable structural lesion and is typically caused by vascular compression of the nerve root, most often by the superior cerebellar artery. This compression leads to focal demyelination and abnormal nerve firing. Symptomatic trigeminal neuralgia presents with similar clinical features but is caused by an identifiable pathology such as multiple sclerosis, tumors (e.g., cerebellopontine angle tumors), aneurysms, or arteriovenous malformations.
Clinically, patients describe sudden, severe, “electric shock–like” pain affecting one or more divisions of the trigeminal nerve. The maxillary (V2) division is most commonly involved, followed by the mandibular (V3) and ophthalmic (V1) divisions. Pain is usually unilateral and may occur spontaneously or be triggered by light stimuli such as talking, chewing, brushing teeth, shaving, or even gentle touch. Episodes last from a fraction of a second up to 2 minutes and can occur multiple times per day. Between episodes, patients are typically pain-free, although chronic cases may develop a persistent dull ache.
The diagnosis is primarily clinical and based on a characteristic history. Physical examination is usually normal; the presence of neurologic deficits or atypical features—such as bilateral symptoms, prolonged pain, or abnormal cranial nerve findings—should prompt evaluation for secondary causes. Trigger points that reproduce the pain are considered highly suggestive of the diagnosis.
Imaging is not always required in classic cases but is recommended when atypical features are present or when secondary causes are suspected. MRI of the brain is particularly useful for identifying structural lesions such as tumors or demyelinating disease like multiple sclerosis.
Management focuses on pain control. First-line therapy is carbamazepine, an anticonvulsant that is highly effective in reducing symptoms. Alternative or adjunctive medications include gabapentin, oxcarbazepine, lamotrigine, phenytoin, and valproic acid, particularly in refractory cases.
Patients who do not respond to medical therapy may require referral for procedural or surgical interventions. These include percutaneous nerve blocks, radiofrequency ablation, or microvascular decompression, which can provide long-term relief in a significant proportion of patients.
Disposition depends on severity and associated findings. Patients with typical features and good response to treatment can be managed as outpatients with follow-up by a primary care physician or neurologist. Admission is indicated if there are focal neurologic deficits, concerning imaging findings, or refractory pain requiring advanced intervention.
Key clinical points include recognizing the classic presentation of unilateral, paroxysmal, shock-like facial pain and identifying trigger points. It is essential to exclude secondary causes, particularly in younger patients or those with abnormal neurologic findings. Carbamazepine remains the cornerstone of therapy, and early treatment can significantly improve quality of life.
0 Comments
